SEC Form 4 · accession 0000903423-16-001314
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
GLAXOSMITHKLINE PLC
10% Owner
Period of report
Oct 18, 2016
Accepted (ET)
Oct 20, 2016 · 5:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $14.00 | Oct 18, 2016 | A | 30,000 | A | — | Oct 18, 2026 | Common Shares | 30,000 | 30,000 | I |
Explanation of responses
- F1This stock option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016. The stock option was granted to Simeon J. George as director's compensation. As a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon J. George is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.